welcome
Reuters

Reuters

Health

Health

Obesity drug maker Novo Nordisk's CEO to step down amid market struggle

Reuters
Summary
Nutrition label

75% Informative

Lars Fruergaard Jorgensen will step down following plunge in company's share price.

Under his leadership, Novo Nordisk became a first -mover in the obesity and diabetes drug market.

Investors have been concerned that Novo 's first -to-market obesity drug is losing its lead to Eli Lilly .

VR Score

85

Informative language

93

Neutral language

12

Article tone

formal

Language

English

Language complexity

48

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links